论文部分内容阅读
药物性胆汁淤积性肝病是以胆管细胞损伤为特征,临床特征为黄疸、瘙痒和碱性磷酸酶(ALP)升高。小于1%的患者可发生胆管消失综合征(VBDS)[1]。药物性肝损伤分型1989年国际医学科学组织理事会(Council for International Organizations of Medical Sciences,CIOMS)对药物性肝损伤(drug-induced liver injury,DILI)进行了分型,2005年美国食品和药品管理局(FDA)药物肝毒性委员会(Drug Hpatoloxicity Steering Committee)作了修订。具体分型为:1肝细胞损伤型,丙氨酸转氨酶(ALT)≥3倍参考范围上限
Drug-induced cholestatic liver disease is characterized by bile duct injury characterized by jaundice, pruritus and increased alkaline phosphatase (ALP). Less than 1% of patients may develop bile duct disappearance syndrome (VBDS) [1]. Drug-Induced Hepatic Injury Types 1989 Drug-induced liver injury (DILI) was classified by the Council for International Organizations of Medical Sciences (CIOMS). In 2005, the United States Food and Drugs The FDA Drug Hpatoloxicity Steering Committee was revised. Specific classification as follows: 1 hepatocellular injury, alanine aminotransferase (ALT) ≥ 3 times the upper limit of the reference range